COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04612413
Recruitment Status : Not yet recruiting
First Posted : November 3, 2020
Last Update Posted : November 4, 2020
Sponsor:
Collaborator:
Cato Research
Information provided by (Responsible Party):
Enlivex Therapeutics Ltd.

Brief Summary:
A phase II, multi-center (approximately 10 sites in Israel), randomized, placebo-controlled, dose- finding study comparing the efficacy, safety and tolerability of different dosing regimens of Allocetra-OTS, in up to 160 adult sepsis patients with organ sysfunction.

Condition or disease Intervention/treatment Phase
Sepsis Community-acquired Pneumonia Organ Dysfunction Syndrome Drug: ALLOCETRA-OTS Other: Placebo Phase 2

Detailed Description:

Up to 160 eligible patients will be allocated in a 1:1:1:1 ratio between the 4 cohorts (up to 40 patients in each cohort). Randomization will be in a double blinding fashion which will be kept until Day 4 followed by a single blinding until the end of the study.

Randomization will be stratified by screening Sequential Organ Failure Assessment (SOFA) score (2-6 vs. 7-9).

Patients will be followed over 28 days for efficacy and continue safety follow up of 12 months from IP administration.

Patients participating in this study, regardless if hospitalized or discharged, will be followed daily through Day 7 (inclusive, short-term follow-up), then on Days 10 (only for patients receiving 2nd dose), Day 14, and Day 28 (medium-term follow-up), , and then at 3 months, 6 months and 12 months (long-term safety follow-up).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 160 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

Up to 160 patients will be allocated in a 1:1:1:1 ratio between the 4 cohorts :

Placebo Single Intravenous (IV) dose of Allocetra-OTS, 5x109 cells Single IV dose of Allocetra-OTS, 10x109 cells Single or two IV doses of Allocetra-OTS, 10x109 cells in each dose

Masking: Double (Participant, Investigator)
Masking Description: Randomization will be in a double blinding fashion which will be kept until study Day 4 followed by a single blinding until the end of the study.
Primary Purpose: Treatment
Official Title: A Phase 2, Multi-Center, Randomized, Placebo-Controlled, Dose-Finding Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients
Estimated Study Start Date : November 15, 2020
Estimated Primary Completion Date : January 31, 2022
Estimated Study Completion Date : December 31, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sepsis

Arm Intervention/treatment
Placebo Comparator: Cohort 1
375 ml Ringer's lactate solution
Other: Placebo
Ringer's Lactate Solution

Experimental: Cohort 2
Single IV dose of Allocetra-OTS contain 5x10^9 cells
Drug: ALLOCETRA-OTS
The product contains allogeneic donor mononuclear enriched cells in the form of a liquid suspension containing early apoptotic cells.
Other Name: Cell based therapy, apoptotic cells

Experimental: Cohort 3
Single IV dose of Allocetra-OTS contain 10x10^9 cells
Drug: ALLOCETRA-OTS
The product contains allogeneic donor mononuclear enriched cells in the form of a liquid suspension containing early apoptotic cells.
Other Name: Cell based therapy, apoptotic cells

Experimental: Cohort 4
Single or two IV doses of Allocetra-OTS contain 10x10^9 cells in each dose
Drug: ALLOCETRA-OTS
The product contains allogeneic donor mononuclear enriched cells in the form of a liquid suspension containing early apoptotic cells.
Other Name: Cell based therapy, apoptotic cells




Primary Outcome Measures :
  1. To compare the safety of different doses and regimens of Allocetra-OTS to that of Placebo in the treatment of organ failure in adult sepsis patients [ Time Frame: 28 days ]
    Number and severity of AEs and SAEs throughout 28 days follow up period

  2. To compare the efficacy of different doses and regimens of Allocetra-OTS to that of Placebo in the treatment of organ failure in adult sepsis patients [ Time Frame: 28 days ]
    Change from baseline in SOFA score throughout 28 days


Secondary Outcome Measures :
  1. compare other clinical manifestations of different doses and regimens of Allocetra-OTS associated with organ failure in sepsis patients [ Time Frame: 28 days ]
    Vasopressor-free days over 28 days.

  2. compare other clinical manifestations of different doses and regimens of Allocetra-OTS associated with organ failure in sepsis patients. [ Time Frame: 28 days ]
    Ventilator-free days over 28 days

  3. compare other clinical manifestations of different doses and regimens of Allocetra-OTS associated with organ failure in sepsis patients [ Time Frame: 28 days ]
    Days without renal replacement therapy (dialysis).

  4. compare other clinical manifestations of different doses and regimens of Allocetra-OTS associated with organ failure in sepsis patients [ Time Frame: 28 days ]
    Time in ICU and time in hospital

  5. compare other clinical manifestations of different doses and regimens of Allocetra-OTS associated with organ failure in sepsis patients [ Time Frame: 28 days ]
    Number of days with creatinine ≤ Baseline levels +20%.

  6. compare other clinical manifestations of different doses and regimens of Allocetra-OTS associated with organ failure in sepsis patients [ Time Frame: 28 days ]
    All-cause mortality at Day 28 following first dose

  7. compare other clinical manifestations of different doses and regimens of Allocetra-OTS associated with organ failure in sepsis patients [ Time Frame: 28 days ]
    Changes in CRP levels

  8. Assess long term safety follow up [ Time Frame: 12 months ]
    Number and severity of AEs and Serious Adverse Events (SAEs) throughout 12 months follow up period



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   45 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female ≥45 years and ≤85 years of age.
  • Suspected, presumed or documented community-acquired pneumonia by imaging.
  • Treatment with antibiotics after at least one course for the suspected infection.
  • Meets Sepsis 3 criteria: the presence of organ dysfunction as identified by a total SOFA score ≥2 points above pre-admission SOFA.
  • Has at least one respiratory SOFA score and at least one additional SOFA in any other organ.
  • Signed written informed consent by the patient, or his/her legal guardian or delayed patient consent (based on MOH guidelines and local Ethics Committee (EC) approval).
  • Child-bearing potential Females must not be lactating or pregnant at Screening, as documented by a negative Beta-Human Chorionic Gonadotropin (ß-hCG) or Human Chorionic Gonadotropin (hCG) blood test.
  • Women of child-bearing potential or males whose partners are women of child-bearing potential, use an effective method of contraception throughout the trial.

Exclusion Criteria:

  • Sepsis due to infection other than lung infection, or sepsis patients where site of infection is unclear or unknown
  • On chronic dialysis.
  • Invasive ventilated patient with PaO2/FiO2 < 100 mmHg
  • Weight <50 kg or >120 kg or Body Mass Index (BMI) >40 kg/m2.
  • SOFA score ≥ 10 at screening (Day -1).
  • Septic shock defined by persisting hypotension requiring vasopressors to maintain MAP ≥65 mmHg and having a serum lactate level >2 mmol/L (18 mg/dL) despite adequate volume resuscitation at screening and on Day 1 prior to IP administration.
  • Surgical intervention, plan for surgical intervention (not including percutaneous procedure such as chest drain), or hospitalization within 30 days prior to diagnosis of sepsis.
  • A known malignancy that is progressing or has required active treatment within the past 3 months.
  • Patient with end-stage disease (unrelated to sepsis) defined as patients who prior to the current hospitalization are expected to live < 6 months (as assessed by the study physician).
  • Known active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or chronic viral infections, such as, Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV) or other chronic infections.
  • Chronic respiratory disease requiring home oxygen therapy on a regular basis for > 6 h/day.
  • Known active upper Gastrointestinal (GI) tract ulceration or hepatic dysfunction including but not limited to biopsy-proven cirrhosis; End-stage cirrhosis (Child Pugh Class C); portal hypertension; episodes of past upper GI bleeding attributed to portal hypertension; or prior episodes of hepatic failure, encephalopathy, or coma.
  • Known New York Heart Association (NYHA) class IV heart failure or unstable angina, ventricular arrhythmias, active ischemic heart disease, or myocardial infarction within six months prior to diagnosis of sepsis.
  • Known immunocompromised state or medications known to be immunosuppressive.
  • Organ allograft or previous history of stem cell transplantation.
  • Participation in an interventional investigational study within 30 days prior to diagnosis of sepsis.
  • Likely to be non-compliant or uncooperative during the study (e.g. substance abuse such as drug or alcohol abuse, uncontrolled psychiatric disorder or any chronic condition that may interfere with study conduct).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04612413


Contacts
Layout table for location contacts
Contact: Odelia Ben Shitrit, MBA 972-548887609 odelia@enlivexpharm.com
Contact: Naama Kama 972523466908 naama@enlivexpharm.com

Sponsors and Collaborators
Enlivex Therapeutics Ltd.
Cato Research
Investigators
Layout table for investigator information
Principal Investigator: Pierre Singer, MD Rabin medical center, Belinson Campus, Petah Tiqwa Isarel
Layout table for additonal information
Responsible Party: Enlivex Therapeutics Ltd.
ClinicalTrials.gov Identifier: NCT04612413    
Other Study ID Numbers: ENX-CL-02-002
First Posted: November 3, 2020    Key Record Dates
Last Update Posted: November 4, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Sepsis
Toxemia
Pneumonia
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Infection
Systemic Inflammatory Response Syndrome
Inflammation
Pathologic Processes